Related Experiment Video
Updated: Jan 29, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Dapagliflozin for the treatment of Type 2 diabetes
1a Section of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, 66 Chancellors Cir, JB838-715 McDermot Avenue Winnipeg MB R3E3P4, Canada.
Abstract:
Dapagliflozin is a sodium glucose co-transporter 2 inhibitor that causes glucose to be lost in the urine. This mechanism of action lowers glucose levels throughout the day and is associated with significant weight loss and moderate blood pressure lowering without increasing heart rate. This class of medications are well tolerated but have a higher incidence of genital tract fungal infections and a slight increase in urinary tract infections that are usually easily treated and not recurrent. Dapagliflozin represents a new medication that should help many individuals with Type 2 diabetes achieve their therapeutic targets.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Psychoneuroimmunology: Diabetes and Cancer
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H

